Literature DB >> 31231788

Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment.

Chunyang Jiang1, Lingxiang Meng2, Bingjun Yang1, Xin Luo3.   

Abstract

In recent years, gene editing, especially that using clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9, has made great progress in the field of gene function. Rapid development of gene editing techniques has contributed to their significance in the field of medicine. Because the CRISPR/Cas9 gene editing tool is not only powerful but also has features such as strong specificity and high efficiency, it can accurately and rapidly screen the whole genome, facilitating the administration of gene therapy for specific diseases. In the field of tumor research, CRISPR/Cas9 can be used to edit genomes to explore the mechanisms of tumor occurrence, development, and metastasis. In these years, this system has been increasingly applied in tumor treatment research. CRISPR/Cas9 can be used to treat tumors by repairing mutations or knocking out specific genes. To date, numerous preliminary studies have been conducted on tumor treatment in related fields. CRISPR/Cas9 holds great promise for gene-level tumor treatment. Personalized and targeted therapy based on CRISPR/Cas9 will possibly shape the development of tumor therapy in the future. In this study, we review the findings of CRISPR/Cas9 for tumor treatment research to provide references for related future studies on the pathogenesis and clinical treatment of tumors.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CRISPR/Cas9; Cancer; gene editing; therapy

Mesh:

Year:  2019        PMID: 31231788     DOI: 10.1111/cge.13589

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  14 in total

Review 1.  The potential application of organoids in breast cancer research and treatment.

Authors:  Nasim Ebrahimi; Alireza Nasr Esfahani; Setare Samizade; Atena Mansouri; Masoud Ghanaatian; Samaneh Adelian; Vida Shadman Manesh; Michael R Hamblin
Journal:  Hum Genet       Date:  2021-10-28       Impact factor: 4.132

Review 2.  CRISPR-Cas and Its Wide-Ranging Applications: From Human Genome Editing to Environmental Implications, Technical Limitations, Hazards and Bioethical Issues.

Authors:  Roberto Piergentili; Alessandro Del Rio; Fabrizio Signore; Federica Umani Ronchi; Enrico Marinelli; Simona Zaami
Journal:  Cells       Date:  2021-04-21       Impact factor: 7.666

3.  Effect of CMB Carrying PTX and CRISPR/Cas9 on Endometrial Cancer Naked Mouse Model.

Authors:  Junhong Cai; Dongcai Wu; Yanbin Jin; Shan Bao
Journal:  J Healthc Eng       Date:  2022-03-25       Impact factor: 2.682

Review 4.  Will CRISPR-Cas9 Have Cards to Play Against Cancer? An Update on its Applications.

Authors:  Precilla S Daisy; Kuduvalli S Shreyas; T S Anitha
Journal:  Mol Biotechnol       Date:  2021-01-01       Impact factor: 2.695

Review 5.  Nanomaterials for Protein Delivery in Anticancer Applications.

Authors:  Anne Yau; Jinhyung Lee; Yupeng Chen
Journal:  Pharmaceutics       Date:  2021-01-25       Impact factor: 6.321

6.  Overcoming multidrug resistance by knockout of ABCB1 gene using CRISPR/Cas9 system in SW620/Ad300 colorectal cancer cells.

Authors:  Zi-Ning Lei; Qiu-Xu Teng; Zhuo-Xun Wu; Feng-Feng Ping; Peng Song; John N D Wurpel; Zhe-Sheng Chen
Journal:  MedComm (2020)       Date:  2021-12-16

Review 7.  Circular RNAs in stem cells: from basic research to clinical implications.

Authors:  Hui-Juan Lu; Juan Li; Guodong Yang; Cun-Jian Yi; Daping Zhang; Fenggang Yu; Zhaowu Ma
Journal:  Biosci Rep       Date:  2022-01-28       Impact factor: 3.840

Review 8.  Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer.

Authors:  Huimin Zhang; Chunhong Qin; Changming An; Xiwang Zheng; Shuxin Wen; Wenjie Chen; Xianfang Liu; Zhenghua Lv; Pingchang Yang; Wei Xu; Wei Gao; Yongyan Wu
Journal:  Mol Cancer       Date:  2021-10-01       Impact factor: 27.401

9.  Modeling pediatric AML FLT3 mutations using CRISPR/Cas12a- mediated gene editing.

Authors:  Natalia Rivera-Torres; Kelly Banas; Eric B Kmiec
Journal:  Leuk Lymphoma       Date:  2020-08-20

Review 10.  Stem cell programs in cancer initiation, progression, and therapy resistance.

Authors:  Tianzhi Huang; Xiao Song; Dandan Xu; Deanna Tiek; Anshika Goenka; Bingli Wu; Namratha Sastry; Bo Hu; Shi-Yuan Cheng
Journal:  Theranostics       Date:  2020-07-09       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.